Oxidative Damage and Antioxidant Mechanisms in COPD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

111 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-04-30

Study Completion Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The environmental pollutants and endogenous reactive oxygen metabolites from inflammatory cells exert substantial pathological effects on the lung cells \[1\]. Oxidative stress (OS) is a major factor that plays a significant role in lung cancer (LC) \[2\], chronic obstructive pulmonary disease (COPD) \[3\] and obstructive sleep apnea syndrome (OSAS) \[4, 5\]. The current evidence suggests that OS takes part in the mechanisms involved in initiation, promotion and progression of respiratory diseases. The major exposures that cause OS can be summarized as smoking, and ambient air pollution that contains particulate matter smaller than aerodynamic diameter of 2.5 µm \[6-8\]. Epidemiological and clinical studies showed that the overall outcome of pulmonary OS is increased mortality due to increased incidence of respiratory diseases \[9\].

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Oxidative Stress, Inflammatory Markers, and Metabolomics Response to Exercise in Patients With COPD

NCT04117412

Chronic Obstructive Pulmonary Disease

COMPLETED NA

Evaluation of Immunological, Microbiological and Metabolomic Profiles in COPD

NCT06826560

COPD Emphysema Chronic Bronchitis +1 more

COMPLETED

The Occurence of Inflammation and Oxidative Stress in Lung Diseases

NCT00512967

Interstitial Lung Diseases Sarcoidosis Idiopathic Pulmonary Fibrosis +1 more

COMPLETED

Genomic/ Proteomic/ Metabonomic Profiling in Chronic Obstructive Pulmonary Disease (COPD)

NCT00655694

Pulmonary Disease, Chronic Obstructive

WITHDRAWN

Evaluation of Reactive Oxygen Metabolites in the Value of COPD

NCT02297633

COPD(Chronic Obstructive Pulmonary Disease)

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Introduction Lung is a particularly important organ because of its interface with the environment. The environmental pollutants and endogenous reactive oxygen metabolites from inflammatory cells exert substantial pathological effects on the lung cells \[1\]. Oxidative stress (OS) is a major factor that plays a significant role in lung cancer (LC) \[2\], chronic obstructive pulmonary disease (COPD) \[3\] and obstructive sleep apnea syndrome (OSAS) \[4, 5\]. The current evidence suggests that OS takes part in the mechanisms involved in initiation, promotion and progression of respiratory diseases. The major exposures that cause OS can be summarized as smoking, and ambient air pollution that contains particulate matter smaller than aerodynamic diameter of 2.5 µm \[6-8\]. Epidemiological and clinical studies showed that the overall outcome of pulmonary OS is increased mortality due to increased incidence of respiratory diseases \[9\].

In OSAS, an episodic hypoxia-reoxygenation cycle occurs during intermittent nocturnal hypoxias that causes the production of reactive oxygen metabolites \[10\]. These metabolites are responsible for the activation of inflammatory cells in OSAS \[11, 12\], and their increased levels eventually cause ischemia-reperfusion injury \[13\], and cellular and DNA damage \[14, 15\]. The latter, is also a significant contributor of LC progression. The DNA damage in the presence of reactive oxygen metabolites yields carcinogenesis by several mechanisms. Some of them are single or double-stranded DNA breaks, and modifications in purines or pyrimidines. Nevertheless, OS is not the only susceptible factor for carcinogenesis, there are also many other pathological mechanisms contributing to cancer development, such as reactive nitrogen species, and involvement of mitochondrial DNA mutations \[16\] in inflammatory conditions. Previous studies reported that LC occurs two-to-five times higher in patients with moderate-to-severe COPD \[17, 18\]. OS is also the main etiological factor of COPD, which is particularly important in the acute exacerbations of the disease \[19\]. The parenchymal damage in COPD includes some mechanisms such as chronic inflammation, OS, deteriorations in the balance of protease and antiprotease activities, and apoptosis \[20\]. The major etiological factor that suspected to play role in the progression of LC in COPD is reported as chronic inflammation, which causes induction of several interleukins and cyclooxygenase-2 activity. The inflammatory micro-environment is a potential medium for contributing the neoproliferative process, which interacts with regulatory mechanism such as apoptosis and angiogenesis \[21\].

Some biomarkers are available for evaluating the OS in the living organisms \[22\]. Some of these biomarkers are malondialdehyde (MDA), 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-OHdG), and coenzyme Q10 (CoQ10). Each of these biomarkers is involved in oxidative processes. MDA is a by-product of polyunsaturated fatty acid peroxidation \[23\]. Lipid peroxidation is the oxidation reactions between reactive oxygen metabolites and polyunsaturated fatty acids, which eventually causes changes in the structure and permeability of lung membrane \[24\]. The second biomarker, 8-OHdG, is primarily involved in DNA damage. The mechanism for this damage is the guanine: cytosine to adenine: thymine transversion on DNA replication \[25\], which induces microsatellite instability, and abnormal apoptosis or necrosis \[26\]. The third biomarker is CoQ10, which is also a mediator of lipid peroxidation, and an essential cofactor in the electron-transport chain (ETC). It is also a lipophilic antioxidant component of the lipid membranes \[27\]. In this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiratory Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.